Tyrosinemia type III: Diagnosis and ten-year follow-up

Acta Paediatrica, International Journal of Paediatrics

Volumn 86, Issue 9, 1997, Pages 1013-1015

  Cerone, R ^a   Holme, E ^b   Schiaffino, M C ^a   Caruso, U ^a   Maritano, L ^a   Romano, C ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

4 Hydroxyphenylpyruvate dioxygenase deficiency; Tyrosinemia type III

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; FUMARYLACETOACETASE; TYROSINE AMINOTRANSFERASE;

ARTICLE; CASE REPORT; CHILD; DIET RESTRICTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FOLLOW UP; HUMAN; MALE; MENTAL DEFICIENCY; NEUROLOGIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; TYROSINEMIA;

EID: 0030803606     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.1997.tb15192.x     Document Type: Article

References (14)

1. Mitchell GA, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 1995.
2. Endo F, Kitano A, Vehara, Nagata N, Matsuda I, Shinka T, et al. Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumary-lacetoacetase: a new variant form of hereditary hypertyrosinemia. Pediatr Res 1983; 17: 92-6
3. Giardini O, Cantani A, Kennaway NG, D'Eufemia P. Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement. Pediatr Res 1983; 17: 25-9
4. Preece MA, Rylance GW, MacDonald A, Green A, Gray RGF. A new case of tyrosinemia type III detected by neonatal screening. J Inher Metab Dis 1996; 19 Suppl 1: 32
5. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992; 340: 813-7
6. Holme E, Linstedt S. Diagnosis and management of tyrosinemia type I Cur Opin Pediatr 1995; 7: 726-32
7. Caruso U, Raverdino V, Romano C. Gaschromatographic/mass spectrometric and gaschromatographic/Fourier transformed infrared analysis of organic acids: preliminary data. Biomed Mass Spectrom 1988; 16: 285-8
8. Ohisalo J, Pispa J. Heterogeneity of hepatic tyrosine aminotransferase. Separation of the multiple forms from rat and frog liver by isoelectric focusing and hydroylapatite column chromatography and their partial characterization. Acta Chem Scand 1976; B 30; 491-500
9. Linblad B, Lindstedt S, Olander B, Omfeldt M. Purification of 4-hydroxyphenylpyruvate hydroxylase from human liver. Acta Chem Scand 1971; 25: 329-30
10. Kvittingen EA, Jellum E, Stokke O. Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta 1981; 115: 311-9
11. D'Eufemia P, Giardini O, Cantani A, Martino F, Finocchiaro R. Autoimmune thyroditis in a case of tyrosinaemia type III. J Inher Metab Dis 1992; 15: 861-2
12. Forster M, Celio MR, Winterhalter KH, Binz H. Cellular location of 'liver specific' antigen. F. Scand J Immunol 1986; 24: 745-50
13. Ruetschi U, Dellsen A, Sahlin P, Stenman G, Rymo L, Lindstedt S. Human 4-hydroxyphenylpyruvate dioxygenase. Primary structure and chromosomal localization of the gene. Eur J Biochem 1993; 213: 1081-9
14. Endo F, Katch H, Yamamoto S, Matsuda I. A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia. Am J Hum Genet 1991; 48: 704-9